Title: Adverse events and Tolerability to Amodiaquine alone or in combination with Artesunate in the treatment of uncomplicated P. falciparum malaria in Ghanaian Children: The effect of CYP450 2C8 Mutation
Author: Okere, Nwanneka E.
Institution: Institute of Tropical Medicine and International Health, Berlin
Graduate date: 2008-12-11 (W3C-DTF)
Document: MScIH Thesis Abstract for Okere Nwanneka E. 05_09_2012.pdf
Amodiaquine–artesunate (AQ-AS) is a widely adopted artemisinin combination therapy (ACT) regimen for the treatment of uncomplicated falciparum malaria in many sub Saharan African countries including Ghana. Amodiaquine (AQ) is almost exclusively metabolised into N-desethylamodiaquine by cytochrome P450 2C8 (CYP2C8)isoform. CYP2C8 variant alleles have been associated with defective metabolism of the anticancer drug paclitaxel. This raises the suspicion of impaired AQ metabolism which could in turn affect both efficacy and the frequency of adverse events (AEs). A high prevalence of the CYP2C8*2 mutation has been found in Ghana. Though ACTs are thought to be widely safe and well tolerated, evidence about safety is largely lacking in relation to this mutation. Here, an assessment of AEs in relation to AQ-based therapies and the influence of CYP2C8 mutations in their occurrence is described, analysed and interpreted using data from a clinical trial carried out in Ghana in 2005. This study is focussed on assessing and comparing the incidence and severity of AEs among participants receiving either AQ alone or AQ-AS. Specifically, the effect of CYP2C8 mutations on the incidence and severity of AEs in the two treatment arms is analysed.
Classification: 2012 (LCSH)
Language: English
Date Of Record Creation: 2012-11-29 06:31:13 (W3C-DTF)
Date Of Record Release: 2012-11-29 06:33:15 (W3C-DTF)
Date Last Modified: 2012-11-29 06:34:49 (W3C-DTF)

Report a Problem with this Resource Record

Log In: